HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat.

Abstract
We have previously shown that intracerebroventricular (i.c.v.) infusion of amyloid-beta (Abeta)1-40 produces oxidative stress and cholinergic dysfunction, as well as learning and memory deficits, in rats. In the present study, effects of a newly synthesized azaindolizinone derivative, spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), were assessed in rats with learning deficits induced by Abeta1-40 or scopolamine. The i.c.v. infusion of Abeta1-40 caused impairments in spontaneous alternation behavior in a Y-maze task, spatial reference and short-term memory in a water-maze task, and retention of passive-avoidance learning. Abeta1-40-infused rats also showed reduction in choline acetyltransferase (ChAT) activity in the medial septum and hippocampus, but not in the basal forebrain and cortex, and a decrease in glutathione S-transferase (GST)-like immunoreactivity in the cortex. Nicotine-stimulated acetylcholine (ACh) release in Abeta1-40-infused rats was lower than that in vehicle-infused rats. Oral administration of ZSET1446 at the dose range of 0.01 to 1 mg/kg ameliorated Abeta1-40-induced learning impairment in Y-maze, water-maze, and passive-avoidance tasks. ZSET1446 reversed the decrease of ChAT activity in the medial septum and hippocampus, GST-like immunoreactivity in the cortex, and nicotine-stimulated ACh release of Abeta1-40-treated rats to the levels of vehicle-infused control rats. Furthermore, 0.001 to 0.1 mg/kg ZSET1446 showed ameliorative effects on learning impairments caused by scopolamine in a passive-avoidance task. These results suggest that ZSET1446 may be a potential candidate for development as a therapeutic agent to manage cognitive impairment associated with conditions such as Alzheimer's disease.
AuthorsYoshimasa Yamaguchi, Hitoshi Miyashita, Hiroko Tsunekawa, Akihiro Mouri, Hyoung-Chun Kim, Kenichi Saito, Toshiyuki Matsuno, Seiichiro Kawashima, Toshitaka Nabeshima
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 317 Issue 3 Pg. 1079-87 (Jun 2006) ISSN: 0022-3565 [Print] United States
PMID16474004 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amyloid beta-Peptides
  • Indans
  • Peptide Fragments
  • Spiro Compounds
  • amyloid beta-protein (1-40)
  • spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one
  • Scopolamine Hydrobromide
  • Choline O-Acetyltransferase
Topics
  • Administration, Oral
  • Amyloid beta-Peptides (toxicity)
  • Animals
  • Behavior, Animal (drug effects)
  • Blotting, Western
  • Brain (drug effects, enzymology)
  • Choline O-Acetyltransferase (metabolism)
  • Cognition (drug effects)
  • Indans (administration & dosage, pharmacology, therapeutic use)
  • Injections, Intraventricular
  • Learning Disorders (chemically induced, drug therapy, physiopathology)
  • Male
  • Maze Learning (drug effects)
  • Memory (drug effects)
  • Motor Activity (drug effects)
  • Peptide Fragments (toxicity)
  • Rats
  • Rats, Wistar
  • Scopolamine Hydrobromide (toxicity)
  • Spiro Compounds (administration & dosage, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: